Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.

× No keyword cloud information.

11 in total

1. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Authors: D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy
Journal: Blood Date: 1997-09-15 Impact factor: 22.113

2. GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes.

Authors: Münci Yağci; Irem Akar; Gülsan Türköz Sucak; Rauf Haznedar
Journal: Leuk Res Date: 2005-07 Impact factor: 3.156

3. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia.

Authors: P Venugopal; S Sivaraman; X K Huang; J Nayini; S A Gregory; H D Preisler
Journal: Leuk Res Date: 2000-05 Impact factor: 3.156

4. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.

Authors: Alessandra Ferrajoli; Michael J Keating; Susan O'Brien; Jorge Cortes; Deborah A Thomas
Journal: Cancer Date: 2011-01-18 Impact factor: 6.860

5. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

Authors: John D Hainsworth; Sharlene Litchy; John H Barton; Gerry Ann Houston; Robert C Hermann; James E Bradof; F Anthony Greco
Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544

6. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.

Authors: Sherif S Farag; Ian W Flinn; Rama Modali; Teresa A Lehman; Donn Young; John C Byrd
Journal: Blood Date: 2003-10-16 Impact factor: 22.113

7. Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy.

Authors: Stefanie Srock; Folke Schriever; Andreas Neubauer; Michael Herold; Dieter Huhn
Journal: Leuk Lymphoma Date: 2007-05

Review 8. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.

Authors: Stephen J Schuster; Parameswaran Venugopal; Julie C Kern; Peter McLaughlin
Journal: Leuk Lymphoma Date: 2008-09

9. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.

Authors: Wen-Kai Weng; Wen-Kai Weng; Ronald Levy
Journal: Leuk Lymphoma Date: 2009-09

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.